CLINICAL TRIALS PROFILE FOR SILODOSIN
✉ Email this page to a colleague
All Clinical Trials for SILODOSIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00224107 ↗ | A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo | Completed | Watson Pharmaceuticals | Phase 3 | 2005-05-01 | A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks. |
| NCT00224120 ↗ | A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo | Completed | Watson Pharmaceuticals | Phase 3 | 2005-05-01 | A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks. |
| NCT00224133 ↗ | The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months | Completed | Watson Pharmaceuticals | Phase 3 | 2005-09-01 | A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety. |
| NCT00359905 ↗ | Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH | Completed | RECORDATI GROUP | Phase 3 | 2006-05-01 | A new drug for the treatment of benign prostatic hyperplasia is compared with placebo and tamsulosin (a drug belonging to the same therapeutic class) for to determine if it is safe and effective (the first phase of the study lasts approximately 18 weeks) and then is used for another 9 months to determine its long-term safety. |
| NCT00359905 ↗ | Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH | Completed | Recordati Industria Chimica e Farmaceutica S.p.A. | Phase 3 | 2006-05-01 | A new drug for the treatment of benign prostatic hyperplasia is compared with placebo and tamsulosin (a drug belonging to the same therapeutic class) for to determine if it is safe and effective (the first phase of the study lasts approximately 18 weeks) and then is used for another 9 months to determine its long-term safety. |
| NCT00740779 ↗ | Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome. | Completed | Watson Pharmaceuticals | Phase 2 | 2008-09-01 | The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo. |
| NCT00793819 ↗ | A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia | Completed | Watson Pharmaceuticals | Phase 2 | 2009-01-01 | Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SILODOSIN
Condition Name
Clinical Trial Locations for SILODOSIN
Trials by Country
Clinical Trial Progress for SILODOSIN
Clinical Trial Phase
Clinical Trial Sponsors for SILODOSIN
Sponsor Name
